Explore more topics
SEC Form 4 research

Scribe Therapeutics, Inc. insider transactions

Inspect Scribe Therapeutics, Inc.'s public SEC insider acquisitions and sales, reporting owners and source receipts.

As of 2026-10-15T08:02:39.132Z

Issuer CIK
0001853921
Reporting owners
20
Officers and directors
7
Jump to a section

What is a Form 4?

Animation: what a Form 4 is, shown with one real example. Sonic Automotive (SAH) reporting owner Paul P. Rusnak bought 13,701 shares at $59.78 on Wednesday, October 7, 2026, transaction code P, an open-market purchase (S is a sale and A is an award from the company). A timeline marks the SEC's two-business-day filing deadline, which ends Friday, October 9. The SEC accepted the Form 4 at 4:33:21 PM ET on October 9, and NexusTrade treats it as public one minute later, at 4:34:21 PM ET. A lamp for NexusTrade's InsiderTrades indicator stays off from the trade date until that moment, then counts one purchase worth 13,701 × $59.78 = $819,045.78.
In this example the shares were bought on Oct 7, 2026, and NexusTrade's InsiderTrades indicator can count the purchase starting at 4:34:21 PM ET on Oct 9, one minute after the SEC accepted the Form 4.

A Form 4 is the SEC filing a company insider, such as an officer, director or 10% owner, uses to report a trade in the company's stock, generally within two business days. The animation follows one real filing as an example: Paul P. Rusnak's purchase of Sonic Automotive (SAH) shares on October 7, 2026.

The same reading applies to every row on this page. The trade date is when the shares changed hands. The available date is when NexusTrade treats the filing as public, and a NexusTrade InsiderTrades indicator counts a purchase (code P) or sale (code S) only from that moment. Code A awards are not counted as purchases.

Read one actual disclosure before using it

Show the table · 1 row, 7 columns

Scroll sideways to compare all columns. Select a heading to sort.

2026-07-302026-07-27AH Bio Fund II, L.P., AH Bio Fund III, L.P., AH Equity Partners Bio II, L.L.C., AH Equity Partners Bio III, L.L.C., Andreessen Marc L, HOROWITZ BENJAMIN AP333,333$15Not reported

First displayed source row from Recent insider disclosures. The full bounded history and coverage notes remain below.

The displayed observation date is 2026-07-27 and its public availability date is 2026-07-30. Subtracting those calendar dates gives 3 days of disclosure lag. Historical public research can use the record from the availability date, rather than backdating knowledge to the observation date. The calendar-day difference does not assert an intraday publication time.

This row is code P: a purchase. A purchase code is only one eligibility check. Confirm reporting-owner role, amendment lineage and coverage before treating it as a strategy input.

Open the linked original receipts to verify the row, then inspect a second record before drawing a pattern. This public filing observation supplies source evidence, not a completed copy-trading return.

Recent insider disclosures

Inspect all 25 displayed rows: Recent insider disclosures

This table includes purchases, sales and awards in the public filing record. Awards and open-market purchases are distinct transaction codes. For historical research, use the public availability date to determine when the transaction was knowable.

Read code P as a purchase, S as a sale and A as an award. An award is an acquisition, but it is not an open-market purchase. Open the filing receipt to check the transaction details.

Scroll sideways to compare all columns. Select a heading to sort.

2026-07-302026-07-27AH Bio Fund II, L.P., AH Bio Fund III, L.P., AH Equity Partners Bio II, L.L.C., AH Equity Partners Bio III, L.L.C., Andreessen Marc L, HOROWITZ BENJAMIN AP333,333$15Not reported
2026-07-302026-07-27GORDON CARL LP1,000,000$15Not reported
2026-07-302026-07-27ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLCP1,000,000$15Not reported
2026-07-292026-07-23Staahl BrettA19,385$0Not reported
2026-07-292026-07-23Staahl BrettA19,385$0Not reported
2026-07-292026-03-13Staahl BrettA4,755$0Not reported
2026-07-292026-07-28Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLCP7,905$18.25Not reported
2026-07-292026-07-24Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLCP50,000$22.31Not reported
2026-07-292026-07-24Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLCP2,333,333$15Not reported
2026-07-282026-07-23Watson James DeanA14,725$0Not reported
2026-07-282026-07-23Parrot DavidP1,333$15Not reported
2026-07-282026-07-23Parrot DavidP1,333$15Not reported
2026-07-282026-07-23Parrot DavidA109,426$0Not reported
2026-07-282026-07-23Parrot DavidA109,426$0Not reported
2026-07-282026-03-13Parrot DavidA8,909$0Not reported
2026-07-282026-07-23Oakes Benjamin L.A429,599$0Not reported
2026-07-282026-07-23Oakes Benjamin L.A264,784$0Not reported
2026-07-282026-03-13Oakes Benjamin L.A12,969$0Not reported
2026-07-282026-07-23Bleharski JoshuaA14,725$0Not reported
2026-07-282026-07-23Lucas SvetlanaP3,000$15Not reported
2026-07-282026-07-23Lucas SvetlanaA109,426$0Not reported
2026-07-282026-07-23Lucas SvetlanaA109,426$0Not reported
2026-07-282026-03-13Lucas SvetlanaA9,547$0Not reported
2026-07-282026-07-23GORDON CARL LA14,725$0Not reported
2026-07-282026-07-23Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLCA14,725$0Not reported

Most recent 90-day source activity, up to 50 rows. No rows means no matching recent records, not no historical activity.

Officers and directors in the directory

Show the table · 8 rows, 3 columns

Scroll sideways to compare all columns. Select a heading to sort.

GORDON CARL L0001282930152
OrbiMed Capital GP VIII LLC000184580495
Aghazadeh Behzad000170181531
Avoro Capital Advisors LLC000163331331
Avoro Ventures LLC00018792533
Lucas Svetlana00017812922
ORBIMED ADVISORS LLC00010559511,020
Parrot David00021279082

Which transactions qualify for the company tracker

The company strategy uses verified officers and directors with qualifying acquisitions at this issuer. Other reporting owners may appear in source records without becoming strategy signals.

Strategy eligibility is held while filing coverage is unresolved.

Historical follower simulations are separate from these source transactions. They do not establish live trading results.